Supplementary Information

Page	Content
2	Supplementary Methods
4	Table S1: Reference range thresholds for MRI metrics of organ impairment
5	Table S2: Baseline characteristics of myeloid cancer patients vs healthy controls
7	Table S3: Clinical characteristics for myeloid cancer patients
10	Table S4: Characteristics of myeloid cancer patients with kidney fibroinflammation
13	Supplementary references

Supplementary methods

Inclusion and exclusion criteria

Inclusion criteria were adults with a myeloid cancer diagnosis, who were able to consent and attend the MRI facility for up to three visit. Exclusion criteria were being cured of blood cancer, contraindications to MRI and any active COVID-19 infection symptoms.

Study recruitment

Quantitative multi-organ MRI (CoverScan, Perspectum, Oxford) was used to assess organ impairment as previously reported [1]. Participants underwent a 40-minute MRI scan of lungs, heart, kidney, liver, pancreas and spleen on 1.5T Siemens scanners at the Oxford Community Diagnostics centre on a MAGNETOM Aera 1.5T or a SIGNA Voyager 1.5T. MR metrics were standardised to deliver a single report interpretable by clinicians. Each report included 49 organ-specific metrics with reference ranges to determine impairment. Matched controls (age and sex) were retrospectively selected from amongst 92 healthy controls (no prior COVID-19 diagnosis, no hospital discharge \geq 4 months prior to enrolment and contraindications to MRI) who underwent CoverScan as part of an earlier prospective study of largely non-hospitalised long COVID patients (NCT04369807) [1].

Imaging Acquisitions

- Cardiac MR imaging involved complete coverage of the heart with a short-axis stack (from the apex to the valve plane) of cine images acquired using cardiac gating, each acquired within a short breath-hold. This acquisition mirrors the one used at the UK Biobank and is a standardized approach [2]. Three short-axis and two long axis cine (HLA and VLA) cardiac T1 maps were also acquired using the MOLLI-T1 approach at the basal, mid, and apical levels of the left ventricle. Three short-axis and two long axis cine (HLA and VLA) at the basal, mid, and apical levels. For cardiac T2 maps, acquired using the fast low angle shot (FLASH) in 3T, at 1.5T scanner, TrueFISP was used (a Siemens version of balanced SSFP).
- Liver and pancreas imaging used the LiverMultiScan acquisition protocol (Perspectum, Oxford, UK), which involves 3 single 2D axial slice breath-held acquisitions that separately are sensitive to the fat content (proton density fat fraction [PDFF]), to T2* (which can yield liver iron content) and a MOLLI-T1 measurement (providing a measurement of tissue water) [3].
- Lungs: Two single slice dynamic cine MR acquisitions were acquired in the coronal plane with a 307ms temporal resolution: one 40 s acquisition with the patient instructed to breathe normally and a second 30 s acquisition with the patient instructed to breathe deeply.
- Kidney: a single coronal view was used to image both kidneys. Imaging contrasts were MOLLI-T1, and a spoiled gradient recalled acquisition (spGR).
- Spleen: Volumetric 3D spGR MRI images for organ length. LiverMultiScan acquisition protocol above was used for spleen T1.

Image Analysis

- Cardiac: Experienced cardiac MRI analysts used CVI42v5.11 (Cardiovascular Imaging Inc, Canada) to trace manually the myocardium in the end-diastolic and end-systolic phases in each of the short-axis views, following the standard UK Biobank evaluation approach as previously described [4]. We reported ventricular function; end systolic and diastolic volume; stroke volume and ejection fraction in both ventricles; left ventricular muscle mass and ventricular max wall thickness and global longitudinal and circumferential 3D strain metrics. Cardiac T1 and T2 measurements were determined as the mean of each of the 16 cardiac segments (of the AHA 17 segment model excluding the apex) [5]. When artefacts were present those measurements were not included in the results.
- Liver Images were analysed by data analysts experienced at using the LiverMultiScan (Perspectum, Oxford, UK) software. This yielded global metrics in each liver of PDFF (proton density fat fraction),

T2*, and cT1 (cT1 is a measurement of T1 that has been corrected for the confounding effects of iron and standardised to 3 Tesla; it is elevated with disease).

- Pancreas images were analysed in an equivalent manner to the above except the software used was not FDA-cleared and iron correction was not performed [6]. The T1 was standardized to 3 Tesla.
- Lung: Patient respiration was assessed by imaging a single 2D coronal slice of the lungs using a 30 second dynamic cine MRI acquisition (with a time resolution of 307ms), during which the patient was instructed to breathe deeply. In-house developed automated segmentation methods were used to segment the lungs and measure their areas in each time frame. Segmentations were reviewed and corrected by trained analysts. From these area vs time measurements, the lung area at maximum inspiration and expiration was measured, as well as a fractional area change (max area min area)/max area.
- Kidney: assessed using in-house tools to fit parametric maps and to allow trained analysts to make measurements. The kidney cortex was manually segmented using the MOLLI-T1 map to guide the boundary. Multiple regions-of-interests were manually placed within the cortex to extract a median value of cortical T1 in each kidney. Volumetric delineations of the kidneys were derived from SPGR MRI images. Automated delineations were produced using a 3D convolutional neural network, trained on expert annotations. Delineations were manually checked, and corrected, if necessary, for each subject.
- Spleen: Volumetric delineations were derived from SPGR MRI images. Automated delineations
 were produced using a 3D convolutional neural network, trained on expert annotations.
 Delineations were manually checked, and corrected, if necessary, for each subject. Spleen T1
 images were analysed in an equivalent manner to liver cT1 and pancreas srT1 except the software
 used was not FDA-cleared and iron correction was not performed.

Reference ranges

All MRI metric reference ranges, but organ volumes, were calculated retrospectively from n=92 healthy controls scanned at 1.5T and 3T based on the 2.5% (lower threshold) and 97.5% percentiles (upper threshold), using bootstrapping (100,000 permutations) [1]. Spleen volumes were calculated from a combined cohort of 92 healthy controls and 1744 BMI-matched participants from the UK Biobank [7], representing all sex and height subgroups, as these are known confounders of organ size [8].

Organ Impairment

Organ impairment was calculated for each organ based on evidence of any of the measurements appearing out of reference range (Supplementary Table 1, essentially as in [1]). Thus, depending on the metric the upper or lower threshold was considered. For cardiac T1 or cardiac T2, elevation in at least 3 AHA segments defined elevated T1. Single organ impairment was based on at least 1 organ impaired and multi-organ impairment was based on 2 organ impairments.

Statistical analysis

We presented the descriptive statistics for continuous and categorical variables with the mean (standard deviation, SD) and frequency (percentage), respectively. For groupwise comparisons, we used Wilcoxon rank sum tests for continuous variables and Fishers exact test for categorical variables. Statistical significance was defined by a p-value threshold of <0.05 (2-sided). All data cleaning and analyses were conducted in R software version 4.2.1.

Metric	Reference range	Definition of impairment		
Liver				
Liver cT1 (ms)	< 800ms	Liver cT1 abnormal AND/OR Liver		
Liver PDFF (%)	< 5%	PDFF abnormal		
Pancreas				
Pancreas srT1 (ms)	< 836ms	Pancreas srT1 abnormal AND/OR		
Pancreas PDFF (%)	< 4%	Pancreas PDFF abnormal		
Heart				
Cardiac T1 segment (ms)	< 1038ms	(≥3 cardiac T1 segments abnormal		
Cardiac T2 segment (ms)	< 58ms	AND ≥3 cardiac segments T2 abnormal)		
Left ventricular ejection fraction (%)	Female: > 52% Male: > 48%	OR (≥3 cardiac T1 segments abnormal		
Right ventricular ejection fraction (%)	Female: > 49% Male: > 50%	 AND [Left ventricular ejection fraction abnormal OR Right ventricular ejection fraction abnormal]) OR (≥3 cardiac T2 segments abnormal AND [Left ventricular ejection fraction abnormal OR Right ventricular ejection fraction abnormal]) 		
Lungs				
Lung fractional area change, right (%)	> 26%	Lung fractional area change, right abnormal AND/OR Lung fractional		
Lung fractional area change, left (%)	> 26%	area change, left abnormal		
Kidney				
Kidney cortical T1, right (ms)	< 1173ms	Kidney cortical T1, right abnormal		
Kidney cortical T1, left (ms)	< 1185ms	AND/OR Kidney cortical T1, left abnormal		
Spleen				
Spleen T1 (ms)	< 1260ms			
Spleen length (cm)	Female (height <164cm): < 11.1cm Female (height ≥164cm): < 12.8cm Male (height <177cm): < 12cm Male (height ≥177cm): < 14cm	Spleen T1 AND/OR spleen length abnormal		

Table S1: Reference range thresholds for MRI metrics of organ impairment

	Healthy controls (n = 35)	Myeloid (n = 26)	P-value Myeloid vs. Healthy controls
	DEMOGRAPHI		Healthy controls
Age [mean (SD)]	52 (7)	55 (13)	0.2
Sex (Male) [n (%)]	12 (34%)	13 (50%)	0.2
BMI (Kg/m ²) [mean (SD)]	23.4 (3.1)	27.5 (6.4)	0.001
	MULTI-ORGAN MRI		
Liver cT1 (ms) [mean (SD)]	686 (42)	734 (93)	0.017
$\geq 800 \text{ms} [n (\%)]$	0 (0%)	4 (16%)	0.026
Liver PDFF (%) [mean (SD)]	2.4 (3.0)	4.3 (4.9)	0.01
≥ 5% [n (%)]	2 (5.7%)	5 (20%)	0.12
Pancreas srT1 (ms) [mean (SD)]	702 (40)	569 (50)	<0.001
$\geq 836ms [n (\%)]$	0 (0%)	0 (0%)	
Pancreas PDFF (%) [mean (SD)]	3.2 (2.4)	4.4 (4.1)	0.5
$\geq 4\% [n (\%)]$	6 (17%)	10 (38%)	0.061
Mean cardiac T1 segment (ms)			
[mean (SD)]	973 (23)	984 (48)	0.2
≥3 cardiac segments ≥1038ms [n (%)] Mean cardiac T2 segment (ms)	1 (2.9%)	4 (15%)	0.15
[mean (SD)]	44.6 (2.1)	48.4 (4.0)	0.024
\geq 3 cardiac segments \geq 58ms [n (%)]	0 (0%)	0 (0%)	-
LV ejection fraction (%) [mean	60.5 (4.1)	58.6 (6.8)	0.18
(SD)] < 48% (Male) or < 52% (Female) [n	00.5 (4.1)	58.0 (0.8)	0.10
(%)]	0 (0%)	2 (8.0%)	1.7
RV ejection fraction (%) [mean (SD)]	57.8 (3.8)	57.3 (7.7)	0.31
< 50% (Male) or $< 49%$ (Female) [n	1 (2.9%)	2 (8.0%)	0.57
(%)] Lung fractional area change, right	1 (2.9%)	2 (8.076)	0.37
(%) [mean (SD)]	45 (10)	42 (8)	0.12
< 26% [n (%)]	2 (5.7%)	0 (0%)	0.5
Lung fractional area change, left (%) [mean (SD)]	47 (11)	44 (10)	0.11
< 26% [n (%)]	2 (5.7%)	1 (4.0%)	>0.9
Kidney cortical T1, right (ms) [mean (SD)]	1,061 (55)	1,145 (75)	<0.001
$\geq 1173 \text{ms} [n (\%)]$	0 (0%)	7 (28%)	0.001
Kidney cortical T1, left (ms) [mean	0 (070)	7 (2070)	0.001
(SD)]	1,072 (51)	1,135 (81)	0.002
$\geq 1185 \text{ms} [n (\%)]$	0 (0%)	6 (24%)	0.004
Spleen T1 (ms) [mean (SD)]	1,125 (71)	1,093 (85)	0.3
≥ 1260ms [n (%)]	1 (2.9%)	0 (0%)	>0.9
Spleen length (cm) [mean (SD)]	9.1 (2.0)	12.8 (3.6)	<0.001
Splenomegaly [n (%)]	2 (5.7%)	11 (44%)	<0.001
	ORGAN ABNORMA		
Liver abnormal [n (%)]	2 (5.7%)	5 (20%)	0.12
Pancreas abnormal [n (%)]	6 (17%)	10 (38%)	0.061
Heart abnormal (Myocarditis) [n (%)]	0 (0%)	3 (12%)	0.07

Table S2: Baseline characteristics of myeloid cancer patients vs healthy controls

	Healthy controls (n = 35)	Myeloid (n = 26)	P-value Myeloid vs. Healthy controls
Lung abnormal [n (%)]	2 (5.7%)	1 (4.0%)	>0.9
Kidney abnormal [n (%)]	0 (0%)	7 (28%)	0.002
Spleen abnormal [n (%)]	3 (8.6%)	11 (44%)	0.002
≥ 1 Organ(s) abnormal [n (%)]	10 (29%)	19 (73%)	<0.001
≥ 2 Organs abnormal [n (%)]	2 (5.7%)	11 (42%)	<0.001

ID	Scan delta (days)	Age (yrs)	Sex	Diagnosis	Mutations	Current Treatment for myeloid neoplasm	Hb (g/L)	WCC (x10* 9/L)	Plat(x10* 9/L)	Neut (x10*9/ L)	Creatinine (μmol/L)	eGFR (mL/ min/ 1.73 m ²)	Bili (μmo I/L)	ALT (U/L)	ALP (IU/L)	MRI abnormality	Comorbidities
002	-	56-60	М	MF	CALR	No treatment	130	8.39	411	5.93	83	100	26	62	81	Spleen, Kidney, Liver, Pancreas & Heart	Asthma, Hypertension & Gout
019	-	76-80	м	MF	JAK2	Hydroxycarba mide	96	1.88	576	1.46	109	57	13	18	60	Spleen & Kidney	None
029	-	46-50	F	MF	N/A	No treatment	NA	NA	NA	NA	NA	NA	NA	NA	NA	Spleen	None
007	-	66-70	F	ET	JAK2, TET2	Hydroxycarba mide	142	6.46	426	4.31	66	77	9	16	59	None	Hypothyroidism
010	-	61-65	F	ET	CALR	Peg Interferon	107	3.91	419	1.17	69	74	5	41	59	Heart	Stroke
014	-	56-60	F	ET	JAK2	Peg Interferon	134	8.56	823	6.06	59	91	11	14	35	Pancreas	Raynaud's
018	-	51-55	F	ET	JAK2	No treatment	128	11.0 2	712	8.23	57	97	10	10	45	Spleen & Kidney	None
020	-	46-50	F	ET	N/A	No treatment	141	12.0 2	771	8.94	47	122	16	16	66	None	None
022	-	41-45	F	ET	CALR	No treatment	141	9.67	540	6.12	64	89	5	13	62	Kidney & Pancreas	Migraines
023	-	46-50	F	ET	N/A	Hydroxycarba mide	146	5.83	508	4.25	44	133	11	29	56	Spleen & Kidney	Coronary artery disease
025	-	51-55	М	ET	JAK2	No treatment	166	9.05	510	5.52	124	53	10	NA	NA	Spleen & Liver	None
027	-	31-35	М	ET	CALR	No treatment	145	6.87	689	4.35	85	90	14	101	89	None	Migraines
001	-	71-75	М	PV	JAK2	No treatment	171	8.01	198	6.22	77	86	22	29	81	Spleen, Liver & Pancreas	2x DVTS
004	-	56-60	F	PV	JAK2 p	No treatment	147	6.46	267	4.07	73	71	10	26	63	None	Hypertension, Diverticulits & Endometriosis
017	-	51-55	М	PV	JAK2	No treatment	131	7.3	507	3.81	75	94	13	25	138	Spleen, Liver & Pancreas	Hypothyroid, Hypertension & Type 2 Diabetes
021	-	71-75	М	PV	N/A	Hydroxycarba mide	140	6.34	435	4.56	82	80	10	13	66	Pancreas	None
024	-	51-55	F	PV	JAK2	No treatment	168	7.73	248	5.25	50	112	11	56	112	Spleen & Liver	Haemochromatosis

Table S3: Clinical characteristics for myeloid cancer patients

008	-	71-75	М	MDS	JAK2 PPM1D	Azacitidine	130	6.06	902	3.67	70	96	7	45	67	Spleen, Kidney, Pancreas & Heart	Prolactinoma & Asthma
015	-	56-60	М	MDS	SF3B1 TET2	Darbepoietin	87	4.35	338	2.57	76	91	31	25	93	Spleen & Pancreas	Myocardial infarction
003	-	46-50	м	CML	N/A	Imatinib	152	6.29	299	4.22	102	68	9	40	53	Pancreas	None
005	-	51-55	F	CML	N/A	Nilotinib	126	6.14	203	3.26	70	75	65	40	52	Pancreas	None
006	-	21-25	F	CML	N/A	Dasatinib	130	4.26	229	1.51	56	115	8	12	31	None	Pulmonary Embolism
009	-	41-45	F	CML	N/A	Imatinib	117	4.2	283	1.93	65	86	9	14	68	Kidney	None
011	-	61-65	м	CML	N/A	Nilotinib	158	9.8	286	6.93	78	87	13	16	109	None	Gout
013	-	41-45	м	CML	N/A	Dasatinib	NA	NA	NA	NA	72	104	9	23	71	None	None
016	-	66-70	м	CML	N/A	Bosutinib	124	8.89	NA	6.55	137	45	9	13	64	Lung	Dyslipidaemia
TP2				1	1				1					1			1
002	182	56-60	М	MF	CALR	No change	126	6.56	416	4.63	87	95	28	71	73	Spleen, Kidney & Liver	No change
019	182	76-80	М	MF	JAK2	Ruxolitinib	94	5.93	304	NA	126	48	6	25	47	Spleen & Kidney	No change
007	203	66-70	F	ET	JAK2 TET2	No change	142	5.31	427	3.23	65	79	6	17	59	Spleen & Kidney	No change
010	266	61-65	F	ET	CALR	No change	112	4.12	303	2.3	69	74	6	31	54	No change	No change
014	182	56-60	F	ET	JAK2	No change	115	4.57	350	2.92	56	97	7	17	52	Kidney, Pancreas & Lung	No change
018	189	51-55	F	ET	JAK2	No change	134	9.6	724	7.2	63	86	9	11	45	Spleen & Kidney	No change
020	245	46-50	F	ET	N/A	No change	137	10.3 3	757	7.25	53	106	18	27	71	None	No change
022	189	41-45	F	ET	CALR	No change	146	7.97	538	4.79	62	92	8	16	55	Kidney	No change
025	182	51-55	м	ET	JAK2	No change	158	10.1 7	671	6.91	84	84	10	38	71	Spleen & Liver	No change
027	196	31-35	М	ET	CALR	Interferon	135	9.61	868	7.88	85	90	12	22	73	Spleen	No change
001	182	71-75	М	PV	JAK2	Hydroxycarba mide	163	5.69	175	4.22	72	93	21	25	74	Spleen, Liver, Pancreas & Lung	No change
004	182	56-60	F	PV	JAK2	No change	155	6.72	259	4.47	63	84	18	28	67	None	No change
017	182	51-55	М	PV	JAK2	No change	140	9.8	502	6.17	67	107	11	25	196	Spleen, Liver & Pancreas	No change

021	217	71-75	М	PV	N/A	No change	138	7.33	418	5.47	75	89	7	15	68	None	No change
008	189	71-75	М	MDS	JAK2 PPM1D	No change	121	7.93	504	4.74	75	89	11	18	59	Spleen, Kidney & Pancreas	Atrial fibrillation and coronary artery thrombus
015	196	56-60	М	MDS	SF3B1 TET2	No change	89	4.98	269	3.18	73	96	29	28	118	Spleen	No change
003	182	46-50	М	CML	N/A	No change	150	6.98	324	3.85	103	67	6	47	45	Pancreas	No change
005	182	51-55	F	CML	N/A	No change	123	6.11	214	3.01	127	38	49	26	57	None	No change
011	301	61-65	м	CML	N/A	No change	151	10.7 6	307	7.75	80	85	6	22	105	None	No change
013	266	41-45	М	CML	N/A	No change	147	4.88	247	2.93	96	75	8	27	77	Kidney & Pancreas	No change
016	182	66-70	М	CML	N/A	No change	123	8.63	244	6.18	137	45	8	12	87	None	No change

Table S4: Characteristics of my	Normal kidney (n = 18)	Abnormal kidney (n = 7)	P-value: Normal vs. Abnormal kidney
	DEMOGRAPI	HICS	
Age [mean (SD)]	54 (13)	56 (14)	>0.9
Sex (Male) [n (%)]	9 (50%)	3 (43%)	>0.9
BMI (Kg/m ²) [mean (SD)]	27.2 (4.0)	27.5 (10.8)	0.3
Categories [n (%)]			0.5
Lean (BMI < 25 Kg/m ²)	5 (28%)	4 (57%)	
Overweight (BMI 25 - 30 Kg/m ²)	9 (50%)	2 (29%)	
Obese (BMI \ge 30 Kg/m ²)	4 (22%)	1 (14%)	
	MYELOID DIAG	INOSIS	
Disease diagnosis			
CML	5 (28%)	1 (14%)	0.6
MDS	1 (5.6%)	1 (14%)	0.5
MF	1 (5.6%)	2 (29%)	0.2
ET	6 (33%)	3 (43%)	0.7
PV	5 (28%)	0 (0%)	0.3
	BLOOD BIOMA	RKERS	
Hb (g/L) [mean (SD)]	140 (22)	127 (17)	0.094
Categories [n (%)]	(/		0.596
<130 g/L [male], <120 g/L [female]	2 (12%)	2 (29%)	
>=130 & <170 g/L [male], >=120 &			
<150 g/L [female] >170 g/L [male],	12 (75%)	5 (71%)	
>150 g/L [female] WCC (x10*9/L) [mean (SD)]	2 (12%)	0 (0%)	0.616
Categories [n (%)]	7.10 (2.12)	6.72 (3.19)	0.616
<4 x10*9/L	- (C 02()		0.352
4 - 11 x10*9/L	1 (6.2%)	1 (14%)	
>11 x10*9/L	14 (88%)	5 (71%)	
	1 (6.2%)	1 (14%)	
Neut (x10*9/L) [mean (SD)]	4.55 (1.98)	4.51 (2.42)	0.922
Categories [n (%)]			0.445
<2 x10*9/L	2 (12%)	2 (29%)	
2 - 7 x10*9/L	13 (81%)	4 (57%)	
>7 x10*9/L	1 (6.2%)	1 (14%)	
Lymph (x10*9/L) [mean (SD)]	1.77 (0.45)	1.50 (0.74)	0.504
Categories [n (%)]			0.304
<1 x10*9/L	0 (0%)	1 (14%)	
1 - 4 x10*9/L	16 (100%)	6 (86%)	
>4 x10*9/L	0 (0%)	0 (0%)	
Platelets (x10*9/L) [mean (SD)]	416 (200)	562 (201)	0.103
Categories [n (%)]			0.176
<150 x10*9/L	0 (0%)	0 (0%)	
150 - 400 x10*9/L	8 (50%)	1 (14%)	

	Normal kidney (n = 18)	Abnormal kidney (n = 7)	P-value: Normal vs. Abnormal kidney
>400 x10*9/L	8 (50%)	6 (86%)	
Creatinine (µmol/L) [mean (SD)]	74 (18)	70 (21)	0.465
Categories [n (%)]			0.194
<59 μmol/L [male], <45 μmol/L [female]	0 (0%)	1 (14%)	
59 - 104 μmol/L [male], 45 - 84 μmol/L [female]	16 (94%)	5 (71%)	
>104 µmol/L [male], >84 µmol/L [female]	1 (5.9%)	1 (14%)	
eGFR (ml/min/{1.73 m2}) [mean (SD)]	88 (18)	94 (22)	0.383
Categories [n (%)]			0.507
<60 (ml/min/{1.73 m²})	1 (5.9%)	1 (14%)	
≥60 (ml/min/{1.73 m²})	16 (94%)	6 (86%)	
Systolic blood pressure (SBP, mmHg) [mean (SD)]	132 (18)	129 (18)	0.856
Categories [n (%)]			>0.999
SBP < 140mmHg	14 (78%)	5 (71%)	
$SBP \ge 140mmHg$ Diastolic blood pressure (SBP,	4 (22%)	2 (29%)	
mmHg) [mean (SD)]	75 (12)	68 (7)	0.161
Categories [n (%)]			>0.999
DBP < 90mmHg	16 (94%)	7 (100%)	
$DBP \ge 90mmHg$	1 (5.9%)	0 (0%)	
	MULTI-ORGAN MR	METRICS	
Liver cT1 (ms) [mean (SD)]	733 (94)	730 (104)	0.7
≥ 800ms [n (%)]	3 (18%)	1 (14%)	>0.9
Liver PDFF (%) [mean (SD)]	4.4 (4.7)	4.4 (6.1)	0.8
≥ 5% [n (%)]	4 (24%)	1 (14%)	>0.9
Pancreas srT1 (ms) [mean (SD)]	551 (35)	609 (63)	0.028
≥ 836ms [n (%)]	0 (0%)	0 (0%)	-
Pancreas PDFF (%) [mean (SD)]	4.2 (3.2)	5.6 (6.2)	>0.9
≥4% [n (%)]	7 (39%)	3 (43%)	>0.9
Mean cardiac T1 segment (ms) [mean (SD)]	981 (38)	991 (68)	0.3
\geq 3 cardiac segments \geq 1038ms [n (%)]	2 (11%)	2 (29%)	0.55
Mean cardiac T2 segment (ms) [mean (SD)]	47.6 (4.1)	50.2 (3.4)	0.14
\geq 3 cardiac segments \geq 58ms [n (%)]	0 (0%)	0 (0%)	-
LV ejection fraction (%) [mean (SD)]	60.3 (6.1)	54.4 (7.2)	0.13
< 48% (Male) or < 52% (Female) [n (%)]	1 (5.6%)	1 (14%)	0.49
RV ejection fraction (%) [mean (SD)]	59 (7)	53 (8)	0.33
< 50% (Male) or < 49% (Female) [n (%)] Lung fractional area change, right	0 (0%)	2 (29%)	0.07
(%) [mean (SD)]	41 (8)	43 (9)	0.5
< 26% [n (%)]	0 (0%)	0 (0%)	-
Lung fractional area change, left (%) [mean (SD)]	42 (9)	50 (9)	0.065

	Normal kidney (n = 18)	Abnormal kidney (n = 7)	P-value: Normal vs. Abnormal kidney
< 26% [n (%)]	0 (0%)	0 (0%)	-
Kidney cortical T1, right (ms) [mean (SD)]	1,108 (49)	1,240 (29)	<0.001
≥ 1173ms [n (%)]	0 (0%)	7 (100%)	<0.001
Kidney cortical T1, left (ms) [mean (SD)]	1,094 (42)	1,240 (57)	<0.001
≥ 1185ms [n (%)]	0 (0%)	6 (86%)	<0.001
Spleen T1 (ms) [mean (SD)]	1,101 (81)	1,091 (95)	0.9
≥ 1251ms [n (%)]	0 (0%)	0 (0%)	-
Spleen length (cm) [mean (SD)]	12.57 (3.71)	13.68 (3.33)	0.3
Splenomegaly [n (%)]	6 (35%)	5 (71%)	0.2
	ORGAN ABNORM	AILITY	
Liver abnormal [n (%)]	4 (24%)	1 (14%)	>0.9
Pancreas abnormal [n (%)]	7 (39%)	3 (43%)	>0.9
Heart abnormal (Myocarditis) [n (%)]	1 (5.6%)	2 (29%)	0.18
Lung abnormal [n (%)]	0 (0%)	0 (0%)	-
Spleen abnormal (Splenomegaly) [n (%)]	6 (35%)	5 (71%)	0.2
\geq 1 Organ(s) abnormal [n (%)]	11 (61%)	7 (100%)	0.13
≥ 2 Organs abnormal [n (%)]	5 (28%)	6 (86%)	0.021

Supplementary references

- Dennis, A, Cuthbertson DJ, Wootton D, et al. Multi-organ impairment and long COVID: a 1year prospective, longitudinal cohort study. Journal of the Royal Society of Medicine. 2023;116(3):97-112. doi:10.1177/01410768231154703
- 2 Petersen SE, Matthews PM, Francis JM, *et al.* UK Biobank's cardiovascular magnetic resonance protocol. *J Cardiovasc Magn Reson* 2016;**18**:8. doi:10.1186/s12968-016-0227-4
- 3 Pavlides M, Banerjee R, Tunnicliffe EM, *et al.* Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. *Liver Int* 2017;**37**:1065–73. doi:10.1111/liv.13284
- 4 Petersen SE, Aung N, Sanghvi MM, *et al.* Reference ranges for cardiac structure and function using cardiovascular magnetic resonance (CMR) in Caucasians from the UK Biobank population cohort. *J Cardiovasc Magn Reson* 2017;**19**:18. doi:10.1186/s12968-017-0327-9
- 5 Cerqueira MD, Weissman NJ, Dilsizian V, *et al.* Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. *Circulation* 2002;**105**:539–42. doi:10.1161/hc0402.102975
- 6 Triay Bagur A, Aljabar P, Ridgway GR, *et al.* Pancreas MRI Segmentation Into Head, Body, and Tail Enables Regional Quantitative Analysis of Heterogeneous Disease. *Journal of Magnetic Resonance Imaging*;**n/a**. doi:10.1002/jmri.28098
- Sudlow C, Gallacher J, Allen N, *et al.* UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS medicine* 2015;**12**:e1001779–e1001779. doi:10.1371/journal.pmed.1001779
- Glodny B, Unterholzner V, Taferner B, *et al.* Normal kidney size and its influencing factors a
 64-slice MDCT study of 1.040 asymptomatic patients. *BMC Urology* 2009;**9**:19–19.
 doi:10.1186/1471-2490-9-19